Please login to the form below
Alnylam
This page shows the latest Alnylam news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and Ionis sign $3.6bn deal for eplontersen
However, if approved, eplontersen will not have the ATTR market to itself and must compete with Pfizer’s Vyndaqel/Vyndamax (tafamidis) and Alnylam’s RNAi therapy Onpattro (patisiran).
Latest news
-
Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn
Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which received approval in hereditary ATTR amyloidosis (hATTR) in 2018.
-
Novo Nordisk hits pause on rival to Hemlibra for haemophilia
Meanwhile, another non-clotting factor drug for haemophilia – Alnylam and Sanofi’s RNA interference candidate fitusiran – is also in late-stage development for haemophilia A and B.
-
China backs use of Roche’s Actemra for coronavirus
In the meantime, Takeda and Alnylam have joined the companies working on drug treatments to tackle COVID-19 infections. ... Alnylam meanwhile says it is working with Vir Biotech on RNA interference drugs targeting ‘highly-conserved regions’ of
-
Alnylam scores EU approval for RNAi drug Givlaari
Alnylam has claimed European Commission approval for its second RNA interface (RNAi) drug Givlaari for acute hepatic porphyria. ... Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar
-
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy
In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
More from news
Approximately 19 fully matching, plus 46 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
2019 was a landmark year for gene-silencing specialist Alnylam and its chief executive John Maraganore. ... It’s all part of a plan that Maraganore thinks could catapult Alnylam into a top five position in the biopharma category within five years,
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Jerini. Commenting on the task ahead at Alnylam, she says: “It’s an incredibly exciting time for the company. ... Alnylam will face a similar process with Europe’s many national HTA organisations.
-
Brexit: the facts (and the alternative facts)
Two post-referendum announcements have boosted the UK Government. GSK announced a £275 million investment in its UK manufacturing sites and Alnylam, a US biotech worth $6.5bn, said it would
-
Managing value: Why early asset development and commercialisation are important
For example, Alnylam Pharmaceuticals, with its lead product in phase III, has a market capitalisation of $7.4bn, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation of
-
Deal Watch table for January 2014
Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products. ... 300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290.
More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Editas Medicine adds to board of directors
Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins. Cambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors. ... He has extensive clinical development experience, a passion for scientific excellence, and
-
VC firm expands team, appoints Genzyme and Lilly veterans
The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies. ... Also joining Third Rock as venture partners are Daniel
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
EPG Health
Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,
-
How do you define a biotech company?
This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where
-
Managing value: Why early asset development and commercialization is important
For example, Alnylam Pharmaceuticals, with its lead product in Phase III, has a market capitalisation of $7.4 billion, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Biogen and Happify Health team up to create digital platform for MS patients
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Moderna to launch Innovation and Technology Center in the UK
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- Gilead Sciences supports Kigali Declaration for neglected tropical diseases
- As the NHS turns 74, it launches its ‘biggest NHS Big Tea ever’ to raise funds
- FDA issues innovative proposal to increase nonprescription drug access
- European Commission approves potential new treatment for Pompe disease
- Connect to the conversation around mental health: A spotlight on physician burnout
- How understanding the rare disease patient’s lived experience creates better health communications
- A creative awakening – how pharma is bringing innovation to the patient journey
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- European Commission approves potential new treatment for Pompe disease
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- FDA issues innovative proposal to increase nonprescription drug access
- Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- Virtual MSL/Sales training programs and events
- Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
- Omnichannel strategies to revolutionize the healthcare professional experience
- Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...
